C4 Therapeutics announced the results of its Annual Meeting of Stockholders held on June 24, 2026, where shareholders approved an amendment to the company's 2020 Stock Option and Incentive Plan. This amendment modifies the plan's "evergreen" provision, which dictates the annual increase in the number of shares available for issuance.
Key Details
- Plan Amendment: The amendment alters the calculation for the annual increase in the share reserve. It will now include shares issuable from any outstanding pre-funded warrants in the total share count used for the calculation, in addition to common stock issued and outstanding.
- Voting Results: The proposal to amend the plan was approved with 33,713,572 votes for and 22,287,787 votes against.
- Other Approvals: Shareholders also elected three Class III directors (Andrew J. Hirsch, Stephen Fawell, Utpal Koppikar), approved executive compensation on an advisory basis, and ratified the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026.